A phone-based video game designed to treat attention attention-deficit/hyperactivity disorder (ADHD) has been granted market clearance from the US Food and Drug Administration (FDA), marking the first-ever over-the-counter (OTC) video game to be cleared by the authority.

Dubbed EndeavorOTC, the game comes in the form of a smartphone app and was cleared through the FDA’s 510(k) pathway after 83% of patients demonstrated a clinical response to the treatment in a clinical trial.

The STARS-ADHD-Adult trial (NCT05183919), also found that nearly three-quarters (72.5%) of patients reported at least some improvement in their quality of life (QoL) by way of the Adult ADHD Quality of Life Scale. A further 45.8% of patients met a prespecified threshold for clinically meaningful improvement.

The game, in the infinite runner genre, is available as part of a subscription model and is available on iOS and Android devices.

CEO of Akili, Matt Franklin said: “This FDA authorisation of EndeavorOTC positions it as a scientifically and clinically validated digital therapy for adult ADHD patients, and we’re incredibly proud of pioneering a new tier of digital medicine.

“This is the culmination of years of clinical studies and the collective effort of scores of technical, scientific, clinical, and regulatory professionals. We are particularly grateful to the patients who participated in the study that made this clearance possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US-based trial enrolled 221 adults with a verified diagnosis of inattentive or combined-type ADHD who all received AKL-T01, the investigational name for the game. The product marks the second of Akali’s digital ADHD therapeutic products to receive FDA clearance.

At the same time the company reports that overall, 11 patients (5%) reported a treatment-emergent adverse device event, most commonly nausea (1.8%) and headache (1.4%), There were no serious adverse device events reported.

The company has also submitted its digital therapeutic SDT-001 for marketing approval with the Japanese Ministry of Health, Labour, and Welfare. Elsewhere in the field of ADHD treatment, German device company Innosphere Engineering has started recruitment for the clinical trial for its electrical stimulation device.